Anthem Biosciences IPO: A Deep Dive into Subscription Status and Market Buzz

The highly anticipated initial public offering (IPO) of Anthem Biosciences Ltd has attracted robust investor interest, especially from the Non-Institutional and Retail segments. As a contract research and development services provider with strong roots in the biopharma sector, Anthem Biosciences is being closely watched for its growth trajectory and strategic listing.

The ₹3,395 crore IPO, which opened on July 14 and closed today on July 16, is an Offer for Sale (OFS) by existing shareholders. No fresh issue of shares is being made. This move aims to provide a partial exit to existing investors, while offering public investors an opportunity to participate in India’s rapidly growing biotech outsourcing industry.

Strong Response: Anthem Biosciences IPO Subscription Status

As of the end of Day 2, the Anthem Biosciences IPO subscription status stood at 3.48 times overall. The retail investor portion was subscribed 2.21 times, showing significant enthusiasm from individual investors. The Non-Institutional Investor (NII) category witnessed a remarkable 10.26 times subscription, signaling high expectations for listing gains and long-term value. However, the Qualified Institutional Buyer (QIB) category was subscribed only 0.62 times, reflecting some cautious sentiment among large institutions.

Market watchers are now waiting for the final Day 3 subscription data to gauge the full strength of demand.

IPO Details at a Glance

• Price Band: ₹445 – ₹468 per share

• Lot Size: 32 shares

• Issue Size: ₹3,395 crore (Offer for Sale)

• Listing Exchanges: BSE and NSE

• Expected Listing Date: July 22, 2025

Grey Market Premium (GMP) and Market Sentiment

The Grey Market Premium (GMP) for Anthem Biosciences IPO has hovered between ₹116 and ₹156 over the past two days, indicating a potential listing price in the range of ₹580–₹620. This implies an approximate listing gain of 20%–27%, which has further fueled demand among retail and NII investors.

Market analysts believe that the company's established track record in drug discovery, manufacturing capabilities, and profit margins make it a premium play in India’s biotech value chain.

Financial Snapshot and Valuation

In FY24–25, Anthem Biosciences reported revenues of over ₹1,840 crore and a profit after tax (PAT) of ₹451 crore, with EBITDA margins hovering around 36%. The IPO values the company at a Price-to-Earnings (P/E) ratio of approximately 70x, which is slightly higher than the sector average but justified given its high growth potential, global clientele, and diversified revenue streams.

Why It Matters for MSME Investors

For Indian MSME owners and retail investors, Anthem Biosciences’ IPO serves as a benchmark for India’s growing dominance in the biopharma outsourcing and CRDMO segment. It is a signal of the increasing investor appetite for science-led companies with scalable operations and global relevance. Moreover, a successful listing could pave the way for more Indian biotech firms to access capital markets, thus boosting innovation in the life sciences ecosystem.

SMEStreet Analysis

Anthem Biosciences is not just another pharma company entering the stock market—it is a symbol of India's capabilities in high-end research and manufacturing services. The strong response to its IPO underscores the confidence of Indian investors in niche, knowledge-driven sectors.

While the anthem biosciences ipo subscription status reflects bullish investor sentiment, the real test will come post-listing when the company is expected to deliver on its promise of sustainable growth. Long-term investors should assess the fundamentals, business moat, and scalability potential before making portfolio decisions.

References:

1. Economic Times – Markets Section

2. LiveMint – IPO Coverage Archive